
TTD - Therapeutic Targets Database Full Data Download File
Version 4.3.02 (2011.08.25)
Provided by BIDD - BioInformatic and Drug Design Group
                   Department of Pharmacy
                   National Unviersity of Singapore
                   http://bidd.nus.edu.sg/group/bidd.htm
Any question about data provided here, please contact with: Prof. Chen (csccyz@nus.edu.sg)


TTDS00001	Name	Muscarinic acetylcholine receptor
TTDS00001	Type of target	Successful target
TTDS00001	Synonyms	(m)AChR
TTDS00001	Synonyms	MAChR
TTDS00001	Disease	Alzheimer's disease
TTDS00001	Disease	Bronchospasm (histamine induced)
TTDS00001	Disease	Glaucoma
TTDS00001	Disease	Motion sickness
TTDS00001	Disease	Obstructive airway disease
TTDS00001	Disease	Organophosphate poisoning
TTDS00001	Disease	Schizophrenia
TTDS00001	Disease	Urinary incontinence
TTDS00001	Disease	Xerostomia
TTDS00001	BioChemical Class	G-protein coupled receptor (rhodopsin family)
TTDS00001	Pathway	Calcium signaling pathway
TTDS00001	Pathway	Neuroactive ligand-receptor interaction
TTDS00001	Pathway	Regulation of actin cytoskeleton
TTDS00001	Related US Patent	6,211,204
TTDS00001	Related US Patent	6,323,194
TTDS00001	Related US Patent	6,369,081
TTDS00001	Related US Patent	6,376,675
TTDS00001	Related US Patent	6,423,842
TTDS00001	Related US Patent	6,451,797
TTDS00001	Related US Patent	6,455,552
TTDS00001	Related US Patent	6,458,812
TTDS00001	Related US Patent	6,555,550
TTDS00001	Related US Patent	6,602,891
TTDS00001	Drug(s)	Bethanechol	DAP000263	Urinary retention	Approved
TTDS00001	Drug(s)	Trospium	DAP000342	Spasm	Approved
TTDS00001	Drug(s)	Oxyphencyclimine	DAP000835	Gastrointestinal disorders	Approved
TTDS00001	Drug(s)	Tridihexethyl	DAP000836	Acquired nystagmus	Approved
TTDS00001	Drug(s)	Anisotropine Methylbromide	DAP000837	Peptic ulcer disease	Approved
TTDS00001	Drug(s)	Hyoscyamine	DAP001108	Gastrointestinal disorders	Approved
TTDS00001	Drug(s)	Methantheline	DAP001109	Irritable bowel syndrome	Approved
TTDS00001	Drug(s)	Procyclidine	DAP001110	Parkinson's disease	Approved
TTDS00001	Drug(s)	Cyclopentolate	DAP001111	Pediatric eye examinations	Approved
TTDS00001	Drug(s)	Ipratropium	DAP001112	Obstructive lung diseases	Approved
TTDS00001	Drug(s)	Pilocarpine	DAP001113	Glaucoma	Approved
TTDS00001	Drug(s)	Flavoxate	DAP001114	Muscle Relaxant	Approved
TTDS00001	Drug(s)	Mepenzolate	DAP001115	Peptic ulcer disease	Approved
TTDS00001	Drug(s)	Ispaghula	DAP001486	Irritable bowel syndrome	Approved
TTDS00001	Drug(s)	Mebeverine	DAP001494	Irritable bowel syndrome	Approved
TTDS00001	Drug(s)	Trihexyphenidyl HCl	DAP001532	Parkinson's Disease	Approved
TTDS00001	Antagonist	Trospium	DAP000342
TTDS00001	Antagonist	Hyoscyamine	DAP001108
TTDS00001	Antagonist	Methantheline	DAP001109
TTDS00001	Antagonist	Procyclidine	DAP001110
TTDS00001	Antagonist	Cyclopentolate	DAP001111
TTDS00001	Antagonist	Ipratropium	DAP001112
TTDS00001	Antagonist	Flavoxate	DAP001114
TTDS00001	Antagonist	Mepenzolate	DAP001115
TTDS00001	Antagonist	Ispaghula	DAP001486
TTDS00001	Antagonist	Mebeverine	DAP001494
TTDS00001	Antagonist	Trihexyphenidyl HCl	DAP001532
TTDS00001	Agonist	Bethanechol	DAP000263
TTDS00001	Agonist	Pilocarpine	DAP001113
TTDS00001	Binder	Oxyphencyclimine	DAP000835
TTDS00001	Binder	Tridihexethyl	DAP000836
TTDS00001	Binder	Anisotropine Methylbromide	DAP000837
TTDS00001	Drug(s)	Aclidinium bromide	DCL000677	Chronic obstructive pulmonary disease	Phase III
TTDS00001	Drug(s)	CHF 5407	DCL000750	Chronic obstructive pulmonary disease	Phase I
TTDS00001	Drug(s)	GSK233705	DCL000823	Chronic obstructive pulmonary disease	Phase II completed
TTDS00001	Drug(s)	NVA237	DCL000901	Chronic obstructive pulmonary disease	Phase III
TTDS00001	Drug(s)	Org-23366	DCL000911	Schizophrenia	No development reported
TTDS00001	Drug(s)	OrM3	DCL000913	Chronic obstructive pulmonary disease	Phase IIb
TTDS00001	Antagonist	Aclidinium bromide	DCL000677
TTDS00001	Antagonist	CHF 5407	DCL000750
TTDS00001	Antagonist	GSK233705	DCL000823
TTDS00001	Antagonist	NVA237	DCL000901
TTDS00001	Antagonist	Org-23366	DCL000911
TTDS00001	Antagonist	OrM3	DCL000913
TTDS00001	Multitarget	Org-23366	DCL000911
TTDS00001	Antagonist	Aprophen	DNC000245
TTDS00001	Antagonist	Benactyzine	DNC000293
TTDS00001	Antagonist	Hyoscine	DNC000757
TTDS00001	Antagonist	Hyoscyamine sulfate	DNC000758
TTDS00001	Antagonist	Ipratropium bromide	DNC000806
TTDS00001	Agonist	Muscarine	DNC000970
TTDS00001	Agonist	RS 86	DNC001236
TTDS00001	Target Validation	TTDS00001
TTDS00002	UniProt ID	P11229
TTDS00002	Name	Muscarinic acetylcholine receptor M1
TTDS00002	Type of target	Successful target
TTDS00002	Synonyms	M1 receptor
TTDS00002	Disease	Alzheimer's disease
TTDS00002	Disease	Bronchospasm (histamine induced)
TTDS00002	Disease	Cognitive deficits
TTDS00002	Disease	Schizophrenia
TTDS00002	Function	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
TTDS00002	Sequence	MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVNNYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLISFDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSSSERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEVVIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKEKKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYALCNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC
TTDS00002	BioChemical Class	G-protein coupled receptor (rhodopsin family)
TTDS00002	Pathway	Calcium signaling pathway
TTDS00002	Pathway	Neuroactive ligand-receptor interaction
TTDS00002	Pathway	Regulation of actin cytoskeleton
TTDS00002	Related US Patent	6,288,068
TTDS00002	Related US Patent	6,294,554
TTDS00002	Related US Patent	6,627,645
TTDS00002	Drug(s)	Pirenzepine	DAP000492	Peptic ulcer disease	Approved
TTDS00002	Drug(s)	Glycopyrrolate	DAP001116	Anesthetic	Approved
TTDS00002	Drug(s)	Clidinium	DAP001117	Abdominal/stomach pain	Approved
TTDS00002	Drug(s)	Dicyclomine	DAP001118	Irritable bowel syndrome	Approved
TTDS00002	Drug(s)	Ethopropazine	DAP001119	Parkinson's disease	Approved
TTDS00002	Drug(s)	Cycrimine	DAP001120	Parkinson's disease	Approved
TTDS00002	Drug(s)	Benztropine	DAP001121	Parkinson's disease	Approved
TTDS00002	Drug(s)	Trihexyphenidyl	DAP001122	Parkinson's disease	Approved
TTDS00002	Drug(s)	Propantheline	DAP001123	Excessive sweating (hyperhidrosis)	Approved
TTDS00002	Drug(s)	Oxyphenonium	DAP001124	Spasm	Approved
TTDS00002	Drug(s)	Biperiden	DAP001125	Parkinson's disease	Approved
TTDS00002	Antagonist	Pirenzepine	DAP000492
TTDS00002	Antagonist	Glycopyrrolate	DAP001116
TTDS00002	Antagonist	Clidinium	DAP001117
TTDS00002	Antagonist	Dicyclomine	DAP001118
TTDS00002	Antagonist	Ethopropazine	DAP001119
TTDS00002	Antagonist	Benztropine	DAP001121
TTDS00002	Antagonist	Trihexyphenidyl	DAP001122
TTDS00002	Antagonist	Propantheline	DAP001123
TTDS00002	Antagonist	Oxyphenonium	DAP001124
TTDS00002	Antagonist	Biperiden	DAP001125
TTDS00002	Binder	Cycrimine	DAP001120
TTDS00002	Drug(s)	Talsaclidine isomer	DCL000268	Alzheimer's disease	Discontinued
TTDS00002	Drug(s)	Sabcomeline hydrochloride	DCL000279	Cardiovascular diseases	Phase IIa
TTDS00002	Drug(s)	Talsaclidine fumarate	DCL000303	Alzheimer's disease	Discontinued
TTDS00002	Drug(s)	Xanomeline tartrate	DCL000328	Alzheimer's disease	Phase II
TTDS00002	Drug(s)	GSK573719	DCL000381	Chronic Obstructive Pulmonary Disease (COPD)	Phase II
TTDS00002	Drug(s)	GSK961081	DCL000397	Chronic Obstructive Pulmonary Disease (COPD)	Phase II completed
TTDS00002	Drug(s)	GSK1034702	DCL000402	Schizophrenia, Dementia	Phase I completed
TTDS00002	Drug(s)	Darotropium	DCL000514	COPD	Suspended in Phase II in GSK 2009 Report
TTDS00002	Drug(s)	Darotropium + 642444	DCL000515	COPD	Phase III
TTDS00002	Drug(s)	Revatropate	DCL000957	Chronic obstructive pulmonary disease	Discontinued in Phase I
TTDS00002	Antagonist	Revatropate	DCL000957
TTDS00002	Agonist	Talsaclidine isomer	DCL000268
TTDS00002	Agonist	Sabcomeline hydrochloride	DCL000279
TTDS00002	Agonist	Talsaclidine fumarate	DCL000303
TTDS00002	Agonist	Xanomeline tartrate	DCL000328
TTDS00002	Agonist	GSK573719	DCL000381
TTDS00002	Agonist	GSK961081	DCL000397
TTDS00002	Agonist	GSK1034702	DCL000402
TTDS00002	Agonist	Darotropium	DCL000514
TTDS00002	Agonist	Darotropium + 642444	DCL000515
TTDS00002	Multitarget	GSK961081	DCL000397
TTDS00002	Multitarget	Revatropate	DCL000957
TTDS00002	Agonist	77-LH-28-1	DNC000099
TTDS00002	Agonist	AC-260584	DNC000137
TTDS00002	Agonist	AC-42	DNC000138
TTDS00002	Agonist	AF150(S)	DNC000165
TTDS00002	Agonist	AF267B	DNC000166
TTDS00002	Agonist	LY-593039	DNC000910
TTDS00002	Agonist	NGX-267	DNC001012
TTDS00002	Agonist	Sabcomeline	DNC001264
TTDS00002	Agonist	WAY-132983	DNC001510
TTDS00002	Inhibitor	Arecoline	DNC002508
TTDS00002	Inhibitor	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DNC003640
TTDS00002	Inhibitor	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DNC003654
TTDS00002	Inhibitor	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DNC003659
TTDS00002	Inhibitor	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	DNC004147
TTDS00002	Inhibitor	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	DNC004159
TTDS00002	Inhibitor	ISOCLOZAPINE	DNC004166
TTDS00002	Inhibitor	SB-202026	DNC004272
TTDS00002	Inhibitor	HIMBACINE	DNC004995
TTDS00002	Inhibitor	RR(17)PZ	DNC005944
TTDS00002	Inhibitor	Bo(15)PZ	DNC005945
TTDS00002	Inhibitor	DIFLUOROBENZTROPINE	DNC005986
TTDS00002	Inhibitor	BI-1356	DNC007901
TTDS00002	Inhibitor	FM1-10	DNC008187
TTDS00002	Inhibitor	FM1-43	DNC008188
TTDS00002	Inhibitor	A-987306	DNC008996
TTDS00002	Inhibitor	GNF-PF-5618	DNC009476
TTDS00002	Inhibitor	CREMASTRINE	DNC009504
TTDS00002	Inhibitor	1,1-diphenyl-2-(3-tropanyl)ethanol	DNC009866
TTDS00002	Inhibitor	R-dimethindene	DNC009877
TTDS00002	Inhibitor	Tiotropium Bromide	DNC009882
TTDS00002	Inhibitor	XANOMELINE	DNC011170
TTDS00002	Inhibitor	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DNC011171
TTDS00002	Inhibitor	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	DNC011427
TTDS00002	Inhibitor	ISOLOXAPINE	DNC011498
TTDS00002	Inhibitor	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	DNC011500
TTDS00002	Inhibitor	CARAMIPEN	DNC011755
TTDS00002	Inhibitor	FLUMEZAPINE	DNC011857
TTDS00002	Inhibitor	AMINOBENZTROPINE	DNC011950
TTDS00002	Inhibitor	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione	DNC012005
TTDS00002	Inhibitor	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	DNC012098
TTDS00002	Inhibitor	SULFOARECOLINE	DNC012122
TTDS00002	Inhibitor	6-Dimethylamino-2-methyl-hex-4-ynal oxime	DNC012306
TTDS00002	Inhibitor	7-Pyrrolidin-1-yl-hept-5-yn-2-one	DNC012322
TTDS00002	Inhibitor	7-Dimethylamino-3-methyl-hept-5-yn-2-one	DNC012323
TTDS00002	Inhibitor	7-Pyrrolidin-1-yl-hept-5-yn-2-one oxime	DNC012330
TTDS00002	Inhibitor	7-Dimethylamino-hept-5-yn-2-one	DNC012350
TTDS00002	Inhibitor	7-Dimethylamino-hept-5-yn-2-one oxime	DNC012351
TTDS00002	Inhibitor	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	DNC012363
TTDS00002	Inhibitor	ACECLIDINE	DNC012502
TTDS00002	Inhibitor	N-methoxyquinuclidine-3-carboximidoyl fluoride	DNC012588
TTDS00002	Inhibitor	BRL-55473	DNC012594
TTDS00002	Inhibitor	N-methoxyquinuclidine-3-carboximidoyl chloride	DNC012616
TTDS00002	Inhibitor	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	DNC012765
TTDS00002	Inhibitor	3alpha-(bis-chloro-phenylmethoxy)tropane	DNC013136
TTDS00002	Inhibitor	3-(3-benzylamino)-piperidin-2-one	DNC013219
TTDS00002	Target Validation	TTDS00002
TTDS00003	UniProt ID	P08172
TTDS00003	Name	Muscarinic acetylcholine receptor M2
TTDS00003	Type of target	Successful target
TTDS00003	Synonyms	M2 receptor
TTDS00003	Disease	Alzheimer's disease
TTDS00003	Disease	Analgesics
TTDS00003	Disease	Autoimmune cardiomyopathy
TTDS00003	Disease	Bronchoconstriction (cold air-induced)
TTDS00003	Disease	Chronic obstructive pulmonary disease, unspecified
TTDS00003	Disease	Hypothermia
TTDS00003	Disease	Neurogenic bladder
TTDS00003	Disease	Pain, unspecified
TTDS00003	Disease	Tremor, unspecified
TTDS00003	Function	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
TTDS00003	Sequence	MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNYFLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQFFSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRIVKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDEITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNIVARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNTVWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR
TTDS00003	PDB Structure	1LUB
TTDS00003	BioChemical Class	G-protein coupled receptor (rhodopsin family)
TTDS00003	Pathway	Calcium signaling pathway
TTDS00003	Pathway	Neuroactive ligand-receptor interaction
TTDS00003	Pathway	Regulation of actin cytoskeleton
TTDS00003	Related US Patent	6,288,068
TTDS00003	Related US Patent	6,294,554
TTDS00003	Related US Patent	6,498,168
TTDS00003	Related US Patent	6,500,822
TTDS00003	Related US Patent	6,627,644
TTDS00003	Related US Patent	6,635,658
TTDS00003	Related US Patent	6,645,958
TTDS00003	Related US Patent	6,667,301
TTDS00003	Drug(s)	Scopolamine	DAP000343	Nausea and Addiction	Approved
TTDS00003	Drug(s)	Methylscopolamine	DAP001126	Peptic ulcer disease	Approved
TTDS00003	Drug(s)	Gallamine Triethiodide	DAP001127	Stabilize muscle contractions	Approved
TTDS00003	Antagonist	Scopolamine	DAP000343
TTDS00003	Antagonist	Methylscopolamine	DAP001126
TTDS00003	Antagonist	Gallamine Triethiodide	DAP001127
TTDS00003	Antagonist	(R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206)	DNC000011
TTDS00003	Antagonist	AF-DX116	DNC000167
TTDS00003	Agonist	CMI-1145	DNC000455
TTDS00003	Agonist	CMI-936	DNC000456
TTDS00003	Antagonist	Otenzepad	DNC001068
TTDS00003	Agonist	Oxotremorine	DNC001081
TTDS00003	Agonist	PTAC	DNC001161
TTDS00003	Inhibitor	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DNC003640
TTDS00003	Inhibitor	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DNC003654
TTDS00003	Inhibitor	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DNC003659
TTDS00003	Inhibitor	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	DNC004147
TTDS00003	Inhibitor	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	DNC004159
TTDS00003	Inhibitor	ISOCLOZAPINE	DNC004166
TTDS00003	Inhibitor	N-DESMETHYLCLOZAPINE	DNC004426
TTDS00003	Inhibitor	SCH-211803	DNC004557
TTDS00003	Inhibitor	METHACHOLINE	DNC004591
TTDS00003	Inhibitor	HIMBACINE	DNC004995
TTDS00003	Inhibitor	METHOCTRAMINE	DNC005816
TTDS00003	Inhibitor	METHOCTRAMINE HYDROCHLORIDE	DNC007831
TTDS00003	Inhibitor	FM1-10	DNC008187
TTDS00003	Inhibitor	FM1-43	DNC008188
TTDS00003	Inhibitor	A-987306	DNC008996
TTDS00003	Inhibitor	GNF-PF-5618	DNC009476
TTDS00003	Inhibitor	1,1-diphenyl-2-(3-tropanyl)ethanol	DNC009866
TTDS00003	Inhibitor	Tiotropium Bromide	DNC009882
TTDS00003	Inhibitor	XANOMELINE	DNC011170
TTDS00003	Inhibitor	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DNC011171
TTDS00003	Inhibitor	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	DNC011427
TTDS00003	Inhibitor	ISOLOXAPINE	DNC011498
TTDS00003	Inhibitor	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	DNC011500
TTDS00003	Inhibitor	CARAMIPEN	DNC011755
TTDS00003	Inhibitor	FLUMEZAPINE	DNC011857
TTDS00003	Inhibitor	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione	DNC012005
TTDS00003	Inhibitor	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	DNC012098
TTDS00003	Inhibitor	SULFOARECOLINE	DNC012122
TTDS00003	Inhibitor	6-Dimethylamino-2-methyl-hex-4-ynal oxime	DNC012306
TTDS00003	Inhibitor	7-Pyrrolidin-1-yl-hept-5-yn-2-one	DNC012322
TTDS00003	Inhibitor	7-Dimethylamino-3-methyl-hept-5-yn-2-one	DNC012323
TTDS00003	Inhibitor	7-Pyrrolidin-1-yl-hept-5-yn-2-one oxime	DNC012330
TTDS00003	Inhibitor	7-Dimethylamino-hept-5-yn-2-one	DNC012350
TTDS00003	Inhibitor	7-Dimethylamino-hept-5-yn-2-one oxime	DNC012351
TTDS00003	Inhibitor	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	DNC012363
TTDS00003	Inhibitor	ACECLIDINE	DNC012502
TTDS00003	Inhibitor	N-methoxyquinuclidine-3-carboximidoyl fluoride	DNC012588
TTDS00003	Inhibitor	BRL-55473	DNC012594
TTDS00003	Inhibitor	N-methoxyquinuclidine-3-carboximidoyl chloride	DNC012616
TTDS00003	Inhibitor	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	DNC012765
TTDS00003	Inhibitor	3-(3-benzylamino)-piperidin-2-one	DNC013219
TTDS00003	Target Validation	TTDS00003
